Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Researchers identify new mechanism that causes leukemia

Every year, 1.1 million new cases of blood cancers are diagnosed worldwide. Presently, chemotherapy remains the most common and effective course of treatment.

13 Aug 2020

Combination regimen improves overall survival in certain patients with AML

A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.

12 Aug 2020

Powerful treatment for IPF stops dangerous scar formation in mouse lungs

A pre-clinical study led by scientists at Cincinnati Children's demonstrates that in mice the drug barasertib reverses the activation of fibroblasts that cause dangerous scar tissue to build up in the lungs of people with idiopathic pulmonary fibrosis (IPF).

6 Aug 2020

ASH publishes new guidelines to help tailor treatment for older adults with acute myeloid leukemia

Today, ASH published new guidelines to help older adults with acute myeloid leukemia (AML) and their health care providers make critical care decisions, including if and how to proceed with cancer treatment and the need for blood transfusions for those in hospice care.

6 Aug 2020

Study could refine treatment recommendations for younger adult patients with acute leukemia

The findings of a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) could refine an important set of prognostic and treatment recommendations for younger adult patients with acute myeloid leukemia (AML.

6 Aug 2020

Study reveals impact of TP53 gene mutations on MDS severity

Considered the "guardian of the genome," TP53 is the most commonly mutated gene in cancer. TP53's normal function is to detect DNA damage and prevent cells from passing this damage on to daughter cells.

3 Aug 2020

Study sheds light on potential new treatment approach in AML patients

Tyrosine kinases are protein enzymes that have many functions within cells, including cell signaling, growth, and division. Sometimes these enzymes can be overactive, which helps cancer cells survive and multiply.

31 Jul 2020

Researchers identify specific target sites for DNA methylases

DNA methylation performs an essential function in mammalian ontogeny. It is also known that abnormalities in this process cause the development of cancers such as leukemia.

22 Jul 2020

Mapping immune landscape of hematological malignancies may help improve cancer therapies

Activating the immune system of the body is a promising form of treatment for cancer. Researchers at the University of Helsinki and Helsinki University Hospital as well as the University of Eastern Finland mapped out the immune landscape of hematological malignancies in a dataset covering more than 10,000 patients to identify drug targets and patient groups which could potentially benefit from immunotherapies.

9 Jul 2020

New nanoconjugate blocks dissemination of tumor cells in animal models of acute myeloid leukemia

The nanoparticle targets only leukemic cells and therefore would reduce the severe adverse effects of current treatments.

9 Jul 2020

Researchers receive innovative grants to understand the biological underpinnings of blood cancers

Seeking to ignite the next major breakthroughs to treat blood cancers, The Leukemia & Lymphoma Society (LLS), The Mark Foundation, and The Paul G. Allen Frontiers Group today announced more than $6.75 million awarded to nine of the most exceptional scientists in the field.

1 Jul 2020

Researchers discover new and improved way to treat poor-prognosis blood cancer

Researchers at Children's Cancer Institute have discovered what could prove a new and improved way to treat the poor-prognosis blood cancer, acute myeloid leukemia or AML.

21 Jun 2020

Researchers call for caution of using CAR-T immunotherapy against AML

Acute myeloid leukemia is a hematological malignancy which incidence increases with age, that is biologically, phenotypically, and genetically very heterogeneous.

17 Jun 2020

Two potent small molecules appear to suppress tumor growth in multiple cancers

City of Hope scientists have identified and developed two potent small molecules that appear to suppress tumor growth in multiple cancers even when other treatments cease to work, possibly due to the development of drug resistance.

16 Jun 2020

New leukemia immune profiles predict drug resistance, positive responses to immunotherapy

By analyzing 442 samples from three groups of children and adults with acute myeloid leukemia (AML), researchers have identified new immune classes of the disease that predict the likelihood of drug resistance and positive responses to immunotherapy.

5 Jun 2020

Researchers discover key gene essential for survival of leukemia stem cells

Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.

3 Jun 2020

KinaRx receives SBIR grant to speed up clinical trials for AML and other diseases

Acute myeloid leukemia (AML), an aggressive blood cancer, is one of the most lethal cancers. More than 19,000 new cases are diagnosed a year, and more than 11,000 people a year die from it, according to the American Cancer Society.

3 Jun 2020

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.

29 May 2020

Combination therapy found to be effective against IDH1-mutated acute myeloid leukemia

A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center.

28 May 2020

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Takeda Pharmaceutical Company Limited today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology, May 29-31 and the 25th Virtual Congress of the European Hematology Association, June 11-14.

18 May 2020

Acute Myeloid Leukemia News and Research

Further Reading

Researchers identify new mechanism that causes leukemia

Combination regimen improves overall survival in certain patients with AML

Powerful treatment for IPF stops dangerous scar formation in mouse lungs

ASH publishes new guidelines to help tailor treatment for older adults with acute myeloid leukemia

Study could refine treatment recommendations for younger adult patients with acute leukemia

Study reveals impact of TP53 gene mutations on MDS severity

Study sheds light on potential new treatment approach in AML patients

Researchers identify specific target sites for DNA methylases

Mapping immune landscape of hematological malignancies may help improve cancer therapies

New nanoconjugate blocks dissemination of tumor cells in animal models of acute myeloid leukemia

Researchers receive innovative grants to understand the biological underpinnings of blood cancers

Researchers discover new and improved way to treat poor-prognosis blood cancer

Researchers call for caution of using CAR-T immunotherapy against AML

Two potent small molecules appear to suppress tumor growth in multiple cancers

New leukemia immune profiles predict drug resistance, positive responses to immunotherapy

Researchers discover key gene essential for survival of leukemia stem cells

KinaRx receives SBIR grant to speed up clinical trials for AML and other diseases

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

Combination therapy found to be effective against IDH1-mutated acute myeloid leukemia

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News